Showing 1011-1020 of 1539 results for "".
- Rinvoq Now Available for Pediatric Patients with Psoriatic Arthritis and Polyarticular Juvenile Idiopathic Arthritishttps://practicaldermatology.com/news/rinvoq-now-available-pediatric-patients-psoriatic-arthritis-and-polyarticular-juvenile-idiopathic-arthritis/2466955/AbbVie announced that its blockbuster drug Rinvoq (upadacitinib) is now indicated in the US for the treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA). The medication is indicated for those who had
- Dapsone Gel Shows Promise for Treating Acne in Skin of Colorhttps://practicaldermatology.com/news/dapsone-gel-shows-promise-treating-acne-skin-color/2463234/A new study in the Journal of Drugs in Dermatology indicates that dapsone gel, 7.5% (Aczone®, Almirall) was safe and effective in the treatment of acne vulgaris in patients with skin of color. "Acne vulgaris is a common skin disease prevalent in skin of color patients
- TODAY Show Feature Criticizes FDA on Sunscreenshttps://practicaldermatology.com/news/today-show-feature-criticizes-fda-sunscreens/2463127/The US Food and Drug Administration (FDA) is doing Americans a disservice by not approving many of the modern sunscreens that are commonly used in Europe, a representative from the Environmental Working Group (EWG) told the TODAY television show last week. “Currently, the US sunscreen mar
- Oral HSP90 Inhibitor Gets Positive Feedback From FDAhttps://practicaldermatology.com/news/oral-hsp90-inhibitor-gets-positive-feedback-fda/2463023/A first-in-class oral drug candidate for the treatment of hidradenitis suppurativa (HS) received positive feedback from a pre-Investigational New Drug meeting with the US Food and Drug Administration (FDA), according to a press release. MC2 Therapeutics, a commercial stage biotech company
- Research Grant Supports Animal-Free Testing for Botoxhttps://practicaldermatology.com/news/research-grant-supports-animal-free-testing-botox/2462979/The National Center for Advancing Translational Services (NCATS) and the US Food and Drug Administration (FDA) awarded a $2 million research grant to develop an advanced testing platform capable of assessing the potency of botulinum toxin without the need for animal testing, according to a press
- Study: OTC Ointment Effective for Hydration and Wound Healing after Dermatologic Procedureshttps://practicaldermatology.com/news/otc-ointment-effective-hydration-wound-headling-dermatologic-procedures/2462940/Results from a two-study analysis in the Journal of Drugs in Dermatology suggested efficacy for an over-the-counter healing ointment (HO; Cetaphil Healing Ointment, Galderma Laboratories, LP, Dallas) in improving skin hydration and wound healing outcomes following dermatologic procedures
- Lilly Resubmits BLA for Lebrikizumabhttps://practicaldermatology.com/news/lilly-resubmits-bla-lebrikizumab/2462907/Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), t
- FDA Accepts sNDA for Dermavant's Tapinarof Cream, 1%https://practicaldermatology.com/news/tapinarof-1-cream-progresses-toward-approval-pediatric-eczema/2462895/The U.S. Food and Drug Administration (FDA) has accepted Dermavant's Supplemental New Drug Application (sNDA) for tapinarof cream, 1% (VTAMA®), for the treatment of atopic dermatitis in (AD), according to a news release from the manufacturer. The FDA assigned a Prescription Drug User Fee
- LEVEL UP: Upadacitinib Shows Superior Efficacy in ADhttps://practicaldermatology.com/news/level-study-upadacitinib-shows-superior-efficacy-ad/2462870/New topline results evaluating the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable suggested that treatment with the drug was effective.<
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru